Interpace Biosciences, Inc. ("Interpace” or the "Company”) (OTCQX: IDXG) today announced preliminary financial and business results for the fiscal year and fourth quarter ended December 31, 2024.

Goldman Sachs analyst Matthew Sykes downgraded Cytek Biosciences Inc (NASDAQ:CTKB) stock rating from Buy to Sell and reduced the price target to $4.50 from the previous $7.00. The downgrade reflects ...

Report with the AI impact on market trends - The global genomics market size is estimated to grow by USD 5.21 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR ...

It will provide two Asian American, Native Hawaiian or Pacific Islander filmmakers with post-production grants of $50,000 ...

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its fourth quarter and year-end 2024 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.

Pacific Biosciences has moved into its new headquarters at 1305 O'Brien Drive in the Menlo Park Labs office complex in Menlo ...

"We are thrilled to welcome Chris to the PacBio Board,” said Christian Henry, President and Chief Executive Officer of PacBio. "Mr. Smith’s deep expertise in clinical diagnostics and genomics, ...

Key Findings Enabled by PacBio Technology: Synchronized Multiomic Sequencing: For the first time, a single sequencing run provided simultaneous insights into genome, methylome, epigenome, and ...

Shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB – Get Free Report) have been given an average rating of ...

Pacific Biosciences of California (PACB) closed at $1.67 in the latest trading session, marking a -1.18% move from the prior day.